Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.44 |
| ▸ | IL1RN | P18510 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.38 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.38 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.38 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.38 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.38 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.38 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.38 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.38 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1405950 | 0.94 | CTSS (0.46) | CTSSPOLBGFERPSMB11PSMA7 | |
| SCHEMBL1406160 | 0.92 | CTSS (0.37) | CTSSIL1RNERAP2ERAP1CACNA1B | |
| SCHEMBL1406173 | 0.91 | CTSS (0.40) | CTSSIL1RNERAP2ERAP1POLB | |
| SCHEMBL1406323 | 0.84 | CTSS (0.40) | CTSSPSMB8 | |
| SCHEMBL2299523 | 0.80 | CTSS (0.50) | CTSSCACNA1BPOLBPSMB11PSMA7 | |
| SCHEMBL1406024 | 0.80 | CTSS (0.44) | CTSSIL1RNERAP2ERAP1CACNA1B | |
| SCHEMBL1406197 | 0.76 | CTSS (0.40) | CTSSCACNA1BPOLBGFERPSMB11 | |
| SCHEMBL1406021 | 0.76 | PSMB5 (0.51) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| Leucine SCHEMBL1406209 | 0.76 | CTSS (0.54) | CTSSCACNA1BPOLBYAP1TACR2 | |
| SCHEMBL1406094 | 0.75 | CTSL (0.41) | CTSSPSMB11PSMA7PSMB1PSMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355910-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | claimed |
| US-20040138411-A1 | Formulation of boronic acid compounds | Government of U.S.A., represented by the Secretary Department of Health & Human Services | 2004-07-15 | — | — | US | claimed |
| US-20040063623-A1 | Formulation of boronic acid compounds | GOV. OF THE U.S.A. REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SVCS. | 2004-04-01 | — | — | US | claimed |
| US-6713446-B2 | BORONIC ACID COMPOUNDS OBTAINED BY LYOPHILIZATION OF AN AQUEOUS MIXTURE OF THE BORONIC ACID COMPOUND AND A SUGAR HAVING AT LEAST TWO HYDROXYL GROUPS; SHELF LIFE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-30 | — | — | US | claimed |
| US-6699835-B2 | BORON COMPOUND FOR USE IN THE TREATMENT OF STROKE, HEART DEFECTS, INFLAMMATION, AUTOIMMUNE AND CANCER DISEASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-02 | — | — | US | claimed |
| EP-1355910-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020188100-A1 | Formulation of boronic acid compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| US-20020169114-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-11-14 | — | — | US | claimed |
| WO-2002059130-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-08-01 | — | — | WO | claimed |
| EP-2251344-B2 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3078667-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3078667-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2251344-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1355910-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | disclosed |
| US-6713446-B2 | BORONIC ACID COMPOUNDS OBTAINED BY LYOPHILIZATION OF AN AQUEOUS MIXTURE OF THE BORONIC ACID COMPOUND AND A SUGAR HAVING AT LEAST TWO HYDROXYL GROUPS; SHELF LIFE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-30 | — | — | US | disclosed |
| US-6699835-B2 | BORON COMPOUND FOR USE IN THE TREATMENT OF STROKE, HEART DEFECTS, INFLAMMATION, AUTOIMMUNE AND CANCER DISEASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-03-02 | — | — | US | disclosed |
| EP-1355910-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020188100-A1 | Formulation of boronic acid compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| US-20020169114-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-11-14 | — | — | US | disclosed |
| WO-2002059130-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188100-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | CTSS 4167/4885IL1RN 4389/4885ERAP2 2504/4885 |
| US-20040138411-A1 | Formulation of boronic acid compounds | SLC10A2, SLC10A1, BTD | CTSS 4208/4885IL1RN 4223/4885ERAP2 3006/4885 |
| US-20040063623-A1 | Formulation of boronic acid compounds | SLC5A1, FBP1, BBC3 | CTSS 3297/4885IL1RN 2408/4885ERAP2 2836/4885 |
| US-20020169114-A1 | Formulation of boronic acid compounds | SLC5A1, FBP1, BBC3 | CTSS 3297/4885IL1RN 2408/4885ERAP2 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.